Medivir AB MVIRB today announces that the development of AL-704
(also known as JNJ-54257099) has been terminated following completion of
phase I clinical studies conducted by Alios Biopharma Inc., one of the
Janssen Pharmaceutical Companies JNJ. These studies demonstrated that AL-704
was safe, well tolerated and had acceptable pharmacokinetic properties.
However its clinical antiviral activity in persons infected with HCV
genotype 1 was insufficient to justify further clinical studies. No
further compounds arising from Medivir's license agreement with Janssen
on HCV NS5B polymerase inhibitors are expected to be progressed into
clinical studies, and therefore no further revenues from this agreement
will be received.
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: NewsPress Releases
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in